BTIG analyst Thomas Shrader maintained a Buy rating on AC Immune SA today and set a price target of $8.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thomas Shrader has given his Buy rating due to a combination of factors including AC Immune SA’s strategic focus on preserving cash and its leadership in developing active immunotherapies for neurodegenerative diseases. The company’s innovative platforms, SupraAntigen and Morphomer, are nearing proof-of-concept data, which could enhance their position in the market. The promising immunogenicity readouts for active immunotherapies targeting Alzheimer’s and Parkinson’s disease patients suggest a potential shift towards less cumbersome treatment options compared to current therapies.
Furthermore, the anti-Aβ ACI-24.060 program has shown immune responses comparable to approved therapies, with no reported ARIA cases, indicating a potentially best-in-class approach. The upcoming data readouts, including those from the PD program and the potential exercise of Takeda’s option, could significantly impact the company’s valuation. With a solid cash position projected to support operations through Q3 2027, AC Immune SA is well-positioned to capitalize on its innovative therapies and partnerships.